| P2093 | author name string | Valentin K Gribkoff | |
| | Michael E Bozik | |
| P2860 | cites work | Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1 | Q22299419 |
| | Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) | Q24246517 |
| | Misfolded CuZnSOD and amyotrophic lateral sclerosis | Q24683677 |
| | The perplexing role of copper-zinc superoxide dismutase in amyotrophic lateral sclerosis (Lou Gehrig's disease) | Q28184546 |
| | From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS | Q28206361 |
| | Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression | Q28215218 |
| | Apoptosis: live or die--hard work either way! | Q28216496 |
| | A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis | Q28240033 |
| | Structure and dynamics of the mitochondrial inner membrane cristae | Q28242621 |
| | TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis | Q28270779 |
| | Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 |
| | Mitochondrial formation of reactive oxygen species | Q29547906 |
| | TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q29615597 |
| | Mitochondria: more than just a powerhouse | Q29617386 |
| | ALS: a disease of motor neurons and their nonneuronal neighbors | Q29618000 |
| | Unraveling the mechanisms involved in motor neuron degeneration in ALS | Q29619073 |
| | Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma | Q30308666 |
| | Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease | Q30441780 |
| | R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. | Q30445597 |
| | Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. | Q30472289 |
| | Mitochondria in sporadic amyotrophic lateral sclerosis | Q30472587 |
| | Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay | Q31105703 |
| | Oxidative stress in amyotrophic lateral sclerosis | Q33906231 |
| | The role of excitotoxicity in ALS--what is the evidence? | Q33906238 |
| | Mitochondria and cell death. | Q33921309 |
| | Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. | Q46377129 |
| | Pramipexole protects against H2O2-induced PC12 cell death | Q46857211 |
| | Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole | Q46890527 |
| | Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. | Q48125844 |
| | Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. | Q48183466 |
| | Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. | Q48186485 |
| | TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation | Q48255479 |
| | Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury | Q48707543 |
| | Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats | Q48726504 |
| | Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons | Q48831389 |
| | An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria | Q54965159 |
| | TDP-43 in differential diagnosis of motor neuron disorders | Q57306374 |
| | Electrophysiological characterization of the Cyclophilin D-deleted mitochondrial permeability transition pore | Q58022739 |
| | Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis | Q70796053 |
| | Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities | Q71572750 |
| | Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons | Q73746646 |
| | Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole | Q74106020 |
| | Mitochondrial DNA deletion mutation levels are elevated in ALS brains | Q74175468 |
| | Amyotrophic lateral sclerosis | Q74486463 |
| | Mitochondrial control of apoptosis: the role of cytochrome c | Q77136010 |
| | Biology and pathology of the mitochondrion | Q77790714 |
| | Mitochondrial dysfunction in Parkinson's disease | Q80228162 |
| | Fine structure of anterior horns in patients without amyotrophic lateral sclerosis | Q93608310 |
| | The internal structure of mitochondria | Q33953227 |
| | Apoptotic and antiapoptotic mechanisms in stroke. | Q33992385 |
| | The mitochondrial permeability transition pore | Q34034610 |
| | Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine | Q34050848 |
| | Mitochondria: execution central | Q34052929 |
| | Import of proteins into mitochondria: a novel pathomechanism for progressive neurodegeneration | Q34280987 |
| | Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). | Q34309512 |
| | Eye movement in amyotrophic lateral sclerosis: a longitudinal study. | Q34391839 |
| | Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. | Q34435972 |
| | Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources | Q34444691 |
| | Mitochondrial degeneration in amyotrophic lateral sclerosis. | Q34551000 |
| | The organization and inheritance of the mitochondrial genome | Q34562809 |
| | Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria | Q34565165 |
| | The permeability transition pore complex: another view. | Q34648839 |
| | Do oxidatively modified proteins cause ALS? | Q34990599 |
| | Genetic epidemiology of amyotrophic lateral sclerosis | Q35083574 |
| | Large-conductance Ca2+- activated K+ channels:physiological role and pharmacology | Q35100652 |
| | Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. | Q35125315 |
| | Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis | Q35137365 |
| | Amyotrophic lateral sclerosis: a review of current concepts. | Q35226371 |
| | Protein aggregation in motor neurone disorders. | Q35592405 |
| | Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance | Q35628041 |
| | Neurodegenerative diseases and oxidative stress | Q35636137 |
| | Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity | Q35693516 |
| | Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins | Q35860305 |
| | New developments in mitochondrial assembly | Q35912801 |
| | Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? | Q35968596 |
| | Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia | Q36016100 |
| | Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia | Q36129202 |
| | The biology and pathology of hypoxia-ischemia: an update. | Q36182924 |
| | mtDNA mutations and common neurodegenerative disorders | Q36254228 |
| | Mitochondrial DNA maintenance and bioenergetics | Q36394452 |
| | The mitochondrial permeability transition from in vitro artifact to disease target | Q36464595 |
| | Transgenic mouse models of amyotrophic lateral sclerosis | Q36468459 |
| | Structure, folding, and misfolding of Cu,Zn superoxide dismutase in amyotrophic lateral sclerosis | Q36524814 |
| | TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis | Q36536399 |
| | Mitochondria in amyotrophic lateral sclerosis: a trigger and a target | Q36565597 |
| | The epidemiology of ALS and the role of population-based registries | Q36637263 |
| | Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases | Q36736582 |
| | Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease | Q36820873 |
| | Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection | Q36862386 |
| | Therapeutic potential of neuronal two-pore domain potassium-channel modulators | Q36894634 |
| | Cognition and amyotrophic lateral sclerosis (ALS). | Q36915818 |
| | Mitochondria: structure and function | Q37557121 |
| | Benzothiazole bipyridine complexes of ruthenium(II) with cytotoxic activity. | Q40127634 |
| | Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. | Q40368104 |
| | Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms | Q40487081 |
| | Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane | Q40615810 |
| | Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection | Q40835830 |
| | Clinical epidemiology of amyotrophic lateral sclerosis | Q40940205 |
| | Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. | Q41152622 |
| | Natural history of ALS: symptoms, strength, pulmonary function, and disability | Q41152646 |
| | Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease | Q41225717 |
| | The pharmacology and mechanism of action of riluzole | Q41263084 |
| | Superoxide dismutase 1 subunits with mutations linked to familial amyotrophic lateral sclerosis do not affect wild-type subunit function. | Q41368778 |
| | Amyotrophic lateral sclerosis. Insights from genetics | Q41619181 |
| | Toxicity of ALS-linked SOD1 mutants | Q41734368 |
| | Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. | Q42252269 |
| | Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors | Q42277766 |
| | Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. | Q42480875 |
| | Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: A temporal study in man | Q42483253 |
| | Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole | Q43574350 |
| | In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production | Q43656976 |
| | Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues | Q43821139 |
| | Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists | Q44434272 |
| | Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms | Q44572475 |
| | The Use of the Potassium Channel Activator Riluzole to Test Whether Potassium Channels Mediate the Capacity of Isoflurane to Produce Immobility | Q44590500 |
| | Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin | Q44807376 |
| | Synthesis and structure-activity relationships of new antimicrobial active multisubstituted benzazole derivatives | Q44819801 |
| | Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. | Q45251257 |
| | Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease | Q45298175 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 215-226 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | CNS Neuroscience & Therapeutics | Q5013184 |
| P1476 | title | KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis | |
| P478 | volume | 14 | |